NCT04014075 - Trastuzumab deruxtecan & Gastric Cancer / Gastric adenocarcinoma (HER2 m) / Stomach cancer, Gastroesophageal junction adenocarcinoma (GEJ)

Allocation: N/A, Interventional Model: Single Group Assignment, Masking: None (Open Label)

Primary outcome measures:
Objective Response Rate (ORR)

Between Nov 26, 2019, and Dec 2, 2020, 89 patients were screened and 79 were enrolled and subsequently treated with trastuzumab deruxtecan (median age 60·7 years [IQR 52·0–68·3], 57 [72%] of 79 were male, 22 [28%] were female, 69 [87%] were White, four [5%] were Asian, one [1%] was Black or African American, one [1%] was Native Hawaiian or Pacific Islander, one had missing race, and three [4%] were other races).

• At the primary analysis (median follow-up 5·9 months [IQR 4·6–8·6 months]), confirmed objective response was reported in 30 (38% [95% CI 27·3–49·6]) of 79 patients, including three (4%) complete responses and 27 (34%) partial responses, as assesse…